GET DAILY SIGNALSBridgeBio Pharma (BBIO) Stock: -10.2% Over 30 Days but +12.6% Quarterly – What Stands Out
Key Takeaways
- BridgeBio Pharma shares declined roughly 10.2% over the trailing 30 days, falling from a closing price of $84.48 on August 7, 2026, to about $75.89.
- Despite the recent pullback, BBIO remains up approximately 12.6% over the trailing quarter, reflecting a broader, multi-month uptrend.
- The short-term decline followed profit-taking after a strong run, an oversubscribed secondary offering by selling stockholder KKR, and fading momentum.
- Second-quarter 2026 revenue rose 120% year over year to $243.7 million, driven by the ATTR-CM therapy Attruby.
- Three late-stage programs are under U.S. FDA review, with BBP-418 carrying a PDUFA target action date of November 27, 2026.
BridgeBio Pharma (BBIO) Company Overview and Market Position
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company headquartered in Palo Alto, California, focused on developing medicines for genetic diseases and cancers. Founded in 2015, the company operates a hub-and-spoke model that spans target identification, preclinical research, clinical development, and commercialization. Its flagship product is Attruby (acoramidis), an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition. The therapy is marketed as Beyonttra in the European Union and Japan. BridgeBio competes in the ATTR-CM market against Pfizer's Vyndaqel/Vyndamax franchise and Alnylam's Amvuttra. Beyond Attruby, the pipeline includes BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), encaleret for autosomal dominant hypocalcemia type 1 (ADH1), and infigratinib for achondroplasia. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
BridgeBio Pharma (BBIO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, BBIO moved from a closing price of $84.48 on August 7, 2026, to approximately $75.89, a decline of about 10.2%. The stock reached an intraday 52-week high around $93 in July before retracing through August and into early September. The quarterly picture is different. About three months earlier, on June 8, 2026, the stock closed at $67.37. Against that level, the current price of roughly $75.89 represents a gain of approximately 12.6%. In short, the recent 30-day decline is a pullback within a still-positive multi-month trend.
What Drove BBIO Stock Price in the Last 30 Days
The 30-day decline reflects a combination of technical, supply, and sentiment factors rather than a single negative clinical event. After a sharp multi-month advance, shares became vulnerable to profit-taking, and the stock recorded a multi-session losing streak through late August and early September. A key supply-side catalyst came on August 14, 2026, when BridgeBio announced the pricing of an oversubscribed secondary offering of 5 million shares by selling stockholder KKR Genetic Disorder L.P. The company received no proceeds from the sale, but the increased float created near-term overhang on the shares. Second-quarter results, reported in early August, were mixed. Total revenue beat expectations at $243.7 million, and Attruby net product revenue reached $222.4 million, more than triple the prior-year figure. However, the company posted a wider-than-expected loss of $0.78 per share as research, development, and commercialization spending rose. This combination of strong top-line growth with persistent operating losses contributed to investor reassessment of near-term valuation.
What Drove BBIO Stock Performance Over the Last Quarter
The broader quarterly gain was driven by sustained commercial execution. Attruby continued to gain first-line market share, and management described it as the fastest-growing brand in the ATTR-CM category. On August 30, 2026, BridgeBio presented new Phase 3 ATTRibute-CM data at the European Society of Cardiology Congress showing durable improvements in cardiac function among acoramidis-treated patients, reinforcing the product's clinical differentiation. The quarter also featured supportive analyst activity. Cantor Fitzgerald reiterated a positive rating with a $110 price target, Mizuho raised its target to $110 from $96, and Wells Fargo raised its target to $102 from $98. A $1 billion preferred equity financing led by Sixth Street closed on July 1, lifting the company's pro forma cash balance to roughly $1.7 billion and supporting plans for three potential launches over the following year.
BBIO Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring BridgeBio should focus on several upcoming milestones. The FDA decision on BBP-418 for LGMD2I is expected by November 27, 2026, and the agency's action on encaleret for ADH1 carries a May 8, 2027 target date. The company has also submitted a new drug application for infigratinib in achondroplasia, with potential approval in mid-2027. Attruby's commercial trajectory remains central, particularly first-line share gains against Pfizer's tafamidis and Alnylam's Amvuttra. Continued revenue growth, progress toward operating break-even, and updates on the chronic hypoparathyroidism Phase 3 program will also shape sentiment. As with any development-stage biopharmaceutical company, regulatory outcomes, clinical data, and capital allocation decisions remain key sources of risk. From what I see, this is important because it highlights the balance between near-term commercial traction and longer-term pipeline catalysts.
Integrating AI Tools Into My Analysis
In my own research on names like BBIO, I often turn to Tickeron’s Trending AI Robots for a curated view of AI-powered trading strategies. The platform highlights top-performing bots across thousands of tickers, with details on strategy, holding periods, and performance metrics that help compare approaches suited to different risk levels and styles. Exploring these options has helped me identify data-driven signals and refine how I evaluate opportunities without replacing my fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for BBIO shows an upward move is likely
BBIO's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 208 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 208 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BBIO as a result. In 73 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
BBIO moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BBIO crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +2.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in 247 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for BBIO moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 20 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for BBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
BBIO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.774) is normal, around the industry mean (3.498). P/E Ratio (-20.868) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing transformative medicines to treat patients who suffer from mendelian diseases.
Industry Biotechnology
Advertisement